Sight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms

Sight Sciences announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis or cyclosporine ophthalmic emulsion 0.05%, prescription eyedrops, Restasis, had additional clinically meaningful improvements in the signs and symptoms of dry eye disease DED when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use. “Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “These data demonstrate superior results with a dry eye treatment technology that is not reliant on patient adherence and supports the case for prioritizing interventional eye lid treatment over a prescription-based approach,” said Brandon Ayres, MD, Co-Director of the Cornea Fellowship Program at Wills Eye Hospital and a Principal Investigator for the SAHARA RCT.